| scholarly article | Q13442814 |
| P2093 | author name string | Shibata R | |
| Miller G | |||
| Maldarelli F | |||
| Martin MA | |||
| Matano T | |||
| Fredrickson T | |||
| Parta M | |||
| Siemon C | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 362-373 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing | |
| P478 | volume | 176 |
| Q33980469 | A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression |
| Q34559322 | A novel protective MHC-I haplotype not associated with dominant Gag-specific CD8+ T-cell responses in SIVmac239 infection of Burmese rhesus macaques |
| Q39193318 | Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. |
| Q33781916 | Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques |
| Q24673961 | All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction |
| Q36092834 | Apoptosis in SIV infection. |
| Q34050712 | Assessment of HIV vaccine development: past, present, and future |
| Q36086627 | Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in burmese rhesus macaques. |
| Q33825229 | Characterization of primary isolate-like variants of simian-human immunodeficiency virus |
| Q33805275 | Characterization of two divergent lineages of macaque rhadinoviruses related to Kaposi's sarcoma-associated herpesvirus |
| Q37547813 | Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells |
| Q34465510 | Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles |
| Q37834099 | Coreceptor use in nonhuman primate models of HIV infection |
| Q36402663 | Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial |
| Q37356010 | Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. |
| Q34970873 | Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies |
| Q24803503 | Development of a real-time QPCR assay for the detection of RV2 lineage-specific rhadinoviruses in macaques and baboons |
| Q35023530 | Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV. |
| Q36473475 | Early Control of Highly Pathogenic Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys Usually Results in Long-Lasting Asymptomatic Clinical Outcomes |
| Q36707305 | Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus |
| Q33807885 | Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). |
| Q39590956 | Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo |
| Q45389776 | Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques. |
| Q39604142 | Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques |
| Q30818112 | Evolution of a human immunodeficiency virus type 1 variant with enhanced replication in pig-tailed macaque cells by DNA shuffling |
| Q40253188 | Expression of simian immunodeficiency virus Nef protein in CD4+ T cells leads to a molecular profile of viral persistence and immune evasion |
| Q34335218 | Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease |
| Q35828002 | Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization |
| Q36934021 | Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial |
| Q39231199 | Generation of a replication-competent chimeric simian-human immunodeficiency virus carrying env from subtype C clinical isolate through intracellular homologous recombination |
| Q33826773 | Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques |
| Q21093217 | Genetic variability of the envelope gene of Type D simian retrovirus-2 (SRV-2) subtypes associated with SAIDS-related retroperitoneal fibromatosis in different macaque species |
| Q34033122 | HIV accessory proteins: multifunctional components of a complex system. |
| Q73890396 | Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV |
| Q39092746 | Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma |
| Q33799497 | Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge |
| Q34120088 | Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus |
| Q34124101 | Immunodeficiency in the absence of high viral load in pig-tailed macaques infected with Simian immunodeficiency virus SIVsun or SIVlhoest |
| Q37333878 | Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques |
| Q35665837 | Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques. |
| Q36949880 | Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response |
| Q45745791 | In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein |
| Q45721995 | In vivo inactivation of Nef ITAM motif of chimeric simian/human immunodeficiency virus SHIVsbg-YE correlates with absence of increased virulence in Chinese rhesus macaques |
| Q34464860 | Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. |
| Q36314997 | Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques |
| Q45479833 | Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus |
| Q37730045 | Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic |
| Q45741830 | Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus |
| Q37248025 | Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease |
| Q84974121 | Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies |
| Q34353521 | Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques |
| Q35897786 | Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. |
| Q35857531 | Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine |
| Q28345408 | Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans |
| Q34226885 | Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages |
| Q37182704 | Macrophages in Progressive Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections |
| Q33842020 | Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus |
| Q34338411 | Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage |
| Q36073984 | Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate |
| Q36438523 | Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains |
| Q33855093 | Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3) |
| Q34712716 | Neutralizing antibodies against HIV -- back in the major leagues? |
| Q39457063 | Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. |
| Q33807535 | Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay |
| Q37743813 | Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques |
| Q54048120 | One-round determination of seven leukocyte subsets in rhesus macaque blood by flow cytometry. |
| Q37120467 | Peripheral edema with hypoalbuminemia in a nonhuman primate infected with simian-human immunodeficiency virus: a case report. |
| Q33816133 | Persistent infection of rhesus macaques by the rev-independent Nef(-) simian immunodeficiency virus SIVmac239: replication kinetics and genomic stability |
| Q33850605 | Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques |
| Q33852768 | Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge |
| Q33792077 | Progress and challenges in therapies for AIDS in nonhuman primate models |
| Q39682485 | Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones |
| Q33647300 | Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. |
| Q29614531 | Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies |
| Q35803633 | Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model |
| Q28366094 | Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous |
| Q35274968 | Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS. |
| Q33648601 | Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. |
| Q33808774 | Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus |
| Q34050736 | Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention |
| Q33810425 | Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques |
| Q35383070 | Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo |
| Q91790814 | The Mtb-HIV syndemic interaction: why treating M. tuberculosis infection may be crucial for HIV-1 eradication |
| Q39595906 | The human immunodeficiency virus type 1 nef gene can to a large extent replace simian immunodeficiency virus nef in vivo. |
| Q37365618 | The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context? |
| Q89574958 | Total body CD4+ T cell dynamics in treated and untreated SIV infection revealed by in vivo imaging |
| Q34391256 | Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. |
| Q38764543 | Use of broadly neutralizing antibodies for HIV-1 prevention |
Search more.